There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
The efficacy of α1 proteinase inhibitor (A1PI) augmentation treatment for α1 antitrypsin
deficiency has not been substantiated by a randomised, placebo-controlled trial. CT-measured
lung density is a more sensitive measure of disease progression in α1 antitrypsin
deficiency emphysema than spirometry is, so we aimed to assess the efficacy of augmentation
treatment with this measure.